Rachelle Suzanne Jacques Akari Therapeutics PLC (AKTX) insider trading activity

Rachelle Suzanne Jacques is Chief Executive Officer of Akari Therapeutics Plc. Currently has a direct ownership of 1.02 Billion shares of AKTX, which is worth approximately $3.16 Billion. The most recent transaction as insider was on Apr 26, 2024, when has been sold 479,569,892 shares (Ordinary shares, par value $0.0001 per share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.02B

n/a 3M change

n/a 12M change

Total Value Held $3.16 Billion

Rachelle Suzanne Jacques Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Apr 26 2024	BUY Grant, award, or other acquisition	-	479,569,892 Added 32.02%	1,018,027,792 Ordinary shares, par v...

Also insider at

QURE

uniQure N.V. Healthcare

Director

CRBP

Corbus Pharmaceuticals Holdings, Inc. Healthcare

VIE

Viela Bio, Inc.

Director

RSJ